The Use of Picato (Ingenol Mebutate) to Treat Actinic Keratosis in Standard Clinical Practice: A Prospective Phase IV, Multicentre, Pan-Hellenic Observational Cohort Study

Trial Profile

The Use of Picato (Ingenol Mebutate) to Treat Actinic Keratosis in Standard Clinical Practice: A Prospective Phase IV, Multicentre, Pan-Hellenic Observational Cohort Study

Completed
Phase of Trial: Phase IV

Latest Information Update: 31 Jan 2018

At a glance

  • Drugs Ingenol mebutate (Primary)
  • Indications Actinic keratosis
  • Focus Therapeutic Use
  • Acronyms PrAKtice
  • Sponsors LEO Pharma
  • Most Recent Events

    • 11 Jan 2018 Status changed from active, no longer recruiting to completed.
    • 03 Jan 2017 Status changed from recruiting to active, no longer recruiting.
    • 02 Mar 2016 Status changed from not yet recruiting to recruiting, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top